Mark Raza Principal Deputy Chief Counsel - FDA | Official Website
Mark Raza Principal Deputy Chief Counsel - FDA | Official Website
This is a 66.7% decrease from the number of companies cited in the previous quarter.
The citations in the county include:
- Procedures have not been adequately established to control product that does not conform to specified requirements.
- Procedures for corrective and preventive action have not been adequately established.
- Complaint files are not adequately maintained.
Most of the companies cited were involved in the Drugs sector.
All of the companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
BioDuro, LLC | Drugs | 02/23/2024 | Procedures not in writing, fully followed |
BioDuro, LLC | Drugs | 02/23/2024 | Equipment Design, Size and Location |
BioDuro, LLC | Drugs | 02/23/2024 | Absence of Written Procedures |
BioDuro, LLC | Drugs | 02/23/2024 | Scientifically sound laboratory controls |
BioDuro, LLC | Drugs | 02/23/2024 | Testing and release for distribution |
BioDuro, LLC | Drugs | 02/23/2024 | Acceptance criteria for sampling & testing |
BioDuro, LLC | Drugs | 02/23/2024 | Records reviewed annually |
BioDuro, LLC | Drugs | 02/23/2024 | Investigations of discrepancies, failures |
Biogennix, LLC | Devices | 02/08/2024 | Nonconforming product, Lack of or inadequate procedures |
Biogennix, LLC | Devices | 02/08/2024 | Lack of or inadequate procedures |
Biogennix, LLC | Devices | 02/08/2024 | Complaints |
Children's Hospital of Orange County | Biologics | 01/16/2024 | Establish, maintain and follow manufacturing SOPs |
Children's Hospital of Orange County | Biologics | 01/16/2024 | Concurrent documentation |
Flavorchem Corporation | Food and Cosmetics | 02/07/2024 | Plant operations - Precautions |
LGM Pharma Solutions, LLC | Drugs | 03/01/2024 | Procedures not in writing, fully followed |
LGM Pharma Solutions, LLC | Drugs | 03/01/2024 | Written procedures not established/followed |
LGM Pharma Solutions, LLC | Drugs | 03/01/2024 | Absence of Written Procedures |
LGM Pharma Solutions, LLC | Drugs | 03/01/2024 | Deviations from laboratory control requirements |